Patient-specific tumor-associated antigens presented on MHC class I and II (TSA/TAA-MHC complex)

Patient-specific tumor-associated antigens (TAAs) and neoantigens presented on MHC class I and II molecules of autologous dendritic cells (DCs) constitute the functional core of personalized cancer vaccines. These antigens are unique to the individual patient's tumor, often arising from somatic mutations (neoantigens) or overexpressed proteins (TAAs), ensuring high specificity and reducing the risk of systemic toxicity (Sahin & Türeci, 2018, Science). In this therapeutic approach, a patient's own dendritic cells are harvested, matured, and loaded with these tumor-specific signals—typically via tumor lysate, synthetic peptides, or mRNA—before being re-infused (Wculek et al., 2020, Nature Reviews Immunology). Once administered, these autologous DCs migrate to the lymph nodes where the MHC-antigen complexes interact directly with T-cell receptors. MHC class I presentation activates CD8+ cytotoxic T cells to directly kill tumor cells, while MHC class II presentation primes CD4+ helper T cells to coordinate a sustained immune response and establish long-term immunological memory (Liau et al., 2018, Journal of Translational Medicine). This dual-pathway activation is critical for overcoming the immunosuppressive tumor microenvironment. Clinical applications of this target complex are currently being explored in various high-grade malignancies, including glioblastoma and metastatic melanoma, where traditional therapies have limited efficacy.

Other names

Neoantigen-MHC complexTumor-specific antigen-MHC complexPersonalized tumor antigensAutologous dendritic cell-presented antigensMHC-peptide complex

Exogenous or endogenous tumor antigens are processed by autologous dendritic cells and loaded onto MHC class I and II molecules for presentation to CD8+ and CD4+ T cells, respectively, to initiate a targeted anti-tumor immune response.